The strong Q1 performance and guidance affirmation support Sanofi's growth trajectory. The successful integration of recent acquisitions and pipeline progress provide confidence in the company's ability to deliver on its 2026 targets. Monitor upcoming regulatory decisions on venglustat and Sarclisa SC as potential catalysts.
Price Chart
Executive Summary
Sanofi reported strong Q1 2026 results with 13.6% sales growth and 14.0% business EPS growth at CER, driven by Dupixent (up 30.8%), Pharma launches (up 49.6%), and pipeline progress. The company affirmed its 2026 guidance.
Key Facts
- Q1 2026 sales grew 13.6% at CER (6.2% at actual exchange rates) to 10.5 billion euros
- Business EPS grew 14.0% at CER to 1.88 euros, up 5.0% at actual exchange rates
- Dupixent sales increased 30.8% to 4.2 billion euros
- Pharma launches sales increased 49.6% to 1.2 billion euros, driven by Ayvakit, ALTUVIIIO, and Sarclisa
- Vaccines sales increased 2.1% to 1.3 billion euros, benefiting from Heplisav-B acquisition
- Company affirmed 2026 guidance: high single-digit sales growth at CER and business EPS growing slightly faster than sales at CER
- Completed acquisition of Dynavax for $2.2 billion and 921 million of 1 billion share buyback program
Financial Impact
Sales increased by 13.6% at constant exchange rates and business EPS increased by 14.0% at constant exchange rates
Risk Factors
- Currency headwinds (estimated at c.-2% on sales and c.-3% on business EPS)
- Increased Regeneron profit sharing impacting business gross profit ratio
- High increase in other operating expenses (up by 62.4%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001121404-26-000004 |
| Document: a6kcoverpagepressreleaseq1.htm | 0001121404-26-000004 |
| Document: 0001121404-26-000004-index-headers.html | 0001121404-26-000004 |
| Document: 0001121404-26-000004-index.html | 0001121404-26-000004 |
| Document: 0001121404-26-000004.txt | 0001121404-26-000004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 8, 2026 20w ago | 6-K | $86.67 $89.80 | ▲ +3.61% | ▲ +0.29% | $84.82 (−2.13%) |
May 27, 2026 21w ago | 6-K | $86.69 $90.53 | ▲ +4.43% | ▲ +2.55% | $84.82 (−2.16%) |
Apr 27, 2026 26w ago | 6-K | $95.06 $88.00 | ▼ −7.43% | ▼ −12.20% | $84.82 (−10.77%) |
Apr 23, 2026 26w ago | 6-K | $92.44 $87.55 | ▼ −5.29% | ▼ −10.31% | $84.82 (−8.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers